Schupp, J.; Weilbaecher, M.; Foerster, F. et al.
Shifting the phenotype of tumor associated macrophages of the metastatic melanoma to overcome immune suppression by applying therapeutic nanoparticlesJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 13. 2015 S. 31-31
Mulder, Chris J.; Schuppan, Detlef
Small Bowel: From Sideline to Center Stage in GastroenterologyDIGESTIVE DISEASES. Bd. 33. H. 2. 2015 S. 113-114
Calvente, Carolina Jimenez; Sehgal, Alfica; Popov, Yury et al.
Specific hepatic delivery of procollagen 1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosisHEPATOLOGY. Bd. 62. H. 4. 2015 S. 1285-1297
Torok, Natalie J.; Dranoff, Jonathan A.; Schuppan, Detlef et al.
Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014HEPATOLOGY. Bd. 62. H. 2. 2015 S. 627-634
Weilbaecher, M.; Bamberger, D.; Schuppan, D. et al.
Targeting tumor-associated M2-macrophages using nanoparticles to improve cancer immunotherapyEXPERIMENTAL DERMATOLOGY. Bd. 24. H. 3. 2015 S. E24-E24
Weng, Shih-Yen; Vijayan, Santosh; Wang, Xiaoyu et al.
The antifibrotic effect of IL-4R alpha signaling depends on macrophage subsets prevalent during liver fibrosis progression and reversalHEPATOLOGY. Bd. 62. 2015 S. 301A-302A
Jia, Jidong; Hou, Jinlin; Ding, Huiguo et al.
Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis BJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. Bd. 30. H. 4. 2015 S. 756-762
Schuppan, Detlef; Zevallos, Victor
Wheat Amylase Trypsin Inhibitors as Nutritional Activators of Innate ImmunityDIGESTIVE DISEASES. Bd. 33. H. 2. 2015 S. 260-263
Schuppan, D.
Which treatments and endpoints for NASH trials are clinically relevant?JOURNAL OF VIRAL HEPATITIS. Bd. 22. 2015 S. 11-11
Kim, Yong Ook; Surabattula, Rambabu; Park, Kyoung-Sook et al.
A Diet-Induced Mouse Model With Development Of Severe NashHEPATOLOGY. Bd. 60. 2014 S. 753A-753A